Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?

1.Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med.1991; 32 :252–4. [PubMed]

2.Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer.1996; 77 :2574–80. [PubMed]

3.McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med.1976; 61 :52–8. [PubMed]

4.Siddiqui AR, Edmondson J, Wellman HN, Hamaker RC, Lingeman RE, Park HM, et al. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med.1981; 6 :158–61. [PubMed]

5.Degroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med.1982; 96 :51–3. [PubMed]

6.Ramacciotti C, Pretorius HT, Line BR, Goldman JM, Robbins J. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: Concise communication. J Nucl Med.1982; 23 :483–9. [PubMed]

7.Becker DV, Hurley JR, Motazedi A, Cahill PT. Ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer can be achieved with less whole-body radiation. J Nucl Med.1982; 23 :43.

8.Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med.1987; 12 :500–2. [PubMed]

9.Leung SF, Law MW, Ho SK. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: A study of 69 cases. Br J Radiol.1992; 65 :905–9. [PubMed]

10.Beierwaltes WH, Rabbani R, Dmuchowski C,

Lloyd RV, Eyre P, Mallette S. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med.1984; 25 :1287–93. [PubMed]

11.Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab.2001; 86 :1447–63. [PubMed]

12.Heidinger LE, Sobin LH.International Histological Classification of Tumors.Geneva: World Health Organization; 1974. pp. 17–26.

13.Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine (Baltimore)1977; 56 :171–96. [PubMed]

14.Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG. Pure follicular thyroid carcinoma: Impact of therapy in 214 patients. J Nucl Med.1980; 21 :733–7. [PubMed]

15.Krishnamurthy GT, Blahd WH. Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study. Cancer.1977; 40 :195–202. [PubMed]

16.Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA.1970; 214 :1437–42. [PubMed]

17.Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med.1978; 8 :79–94. [PubMed]

18.Pochin EE. The occurrence of leukemia following radioiodine therapy. In: Pitt-Rivers R, editor.Advances in Thyroid Research.Oxford: Pergamon Press; 1961. pp. 392–7.

19.Brincker H, Hansen HS, Andersen AP. Induction of leukemia by 131-I treatment of thyroid carcinoma. Br J Cancer.1973; 28 :232–7. [PMC free article] [PubMed]

20.Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med.1976; 17 :460–4. [PubMed]

Category: Cancer-2

Similar articles: